Your browser is no longer supported. Please, upgrade your browser.
LXRX Lexicon Pharmaceuticals, Inc. daily Stock Chart
LXRX [NASD]
Lexicon Pharmaceuticals, Inc.
Index- P/E3.11 EPS (ttm)0.62 Insider Own1.40% Shs Outstand106.54M Perf Week-3.05%
Market Cap200.23M Forward P/E- EPS next Y-0.83 Insider Trans0.00% Shs Float101.38M Perf Month-9.91%
Income85.30M PEG- EPS next Q-0.62 Inst Own99.10% Short Float10.35% Perf Quarter-31.17%
Sales320.90M P/S0.62 EPS this Y197.90% Inst Trans-2.21% Short Ratio10.96 Perf Half Y-45.58%
Book/sh0.51 P/B3.75 EPS next Y60.50% ROA23.30% Target Price- Perf Year-66.25%
Cash/sh2.38 P/C0.80 EPS next 5Y- ROE125.60% 52W Range1.13 - 6.72 Perf YTD-53.98%
Dividend- P/FCF- EPS past 5Y23.30% ROI40.70% 52W High-71.58% Beta1.12
Dividend %- Quick Ratio3.60 Sales past 5Y69.70% Gross Margin99.00% 52W Low69.78% ATR0.16
Employees184 Current Ratio3.60 Sales Q/Q-13.00% Oper. Margin30.10% RSI (14)46.55 Volatility7.29% 7.35%
OptionableYes Debt/Eq4.47 EPS Q/Q-204.20% Profit Margin26.60% Rel Volume1.80 Prev Close2.03
ShortableYes LT Debt/Eq4.28 EarningsApr 27 BMO Payout0.00% Avg Volume957.18K Price1.91
Recom2.80 SMA20-2.65% SMA50-3.26% SMA200-34.15% Volume1,724,062 Change-5.91%
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Mar-25-19Upgrade Gabelli & Co Sell → Hold
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-28-15Upgrade Gabelli & Co Sell → Hold
Sep-18-15Downgrade Gabelli & Co Hold → Sell
Aug-10-15Downgrade JP Morgan Overweight → Neutral
Aug-19-14Downgrade Gabelli & Co Buy → Hold
Jun-26-12Reiterated Stifel Nicolaus Buy $3 → $4
May-27-20 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
May-13-20 05:30PM  Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyls Antiproliferative Effects Against Various Cancer Cell Lines GlobeNewswire
May-04-20 05:46PM  Edited Transcript of LXRX earnings conference call or presentation 27-Apr-20 12:00pm GMT Thomson Reuters StreetEvents
Apr-27-20 06:33PM  US Indexes Start the Week Higher GuruFocus.com +12.20%
04:24PM  Why Lexicon Pharmaceuticals Stock Soared Today Motley Fool
08:15AM  Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:43AM  Lexicon Pharmaceuticals: Q1 Earnings Insights Benzinga
07:00AM  LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE GlobeNewswire
Apr-22-20 05:41PM  Lexicon Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast On April 27, 2020 GlobeNewswire -5.10%
Apr-20-20 10:04AM  The Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Is Down 88% So Some Shareholders Are Rather Upset Simply Wall St.
Apr-07-20 07:00AM  LEXICON PHARMACEUTICALS TO HOST VIRTUAL ANNUAL MEETING OF STOCKHOLDERS ON APRIL 23, 2020 GlobeNewswire -5.91%
Mar-30-20 11:11AM  Edited Transcript of LXRX earnings conference call or presentation 12-Mar-20 12:00pm GMT Thomson Reuters StreetEvents
Mar-20-20 07:44AM  The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company Benzinga -14.83%
Mar-19-20 04:01PM  LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM GlobeNewswire
Mar-13-20 08:05AM  LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYLS ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME GlobeNewswire +5.18%
Mar-12-20 01:40PM  Lexicon Pharmaceuticals: Q4 Earnings Insights Benzinga -14.98%
09:35AM  Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue Estimates Zacks
07:00AM  LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE GlobeNewswire
Mar-05-20 07:00AM  Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call and Webcast on March 12, 2020 GlobeNewswire -6.46%
Mar-04-20 12:30PM  Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for Zacks
Jan-24-20 03:00PM  Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyls Antiproliferative Effects in Patients With Carcinoid Syndrome GlobeNewswire
Jan-20-20 04:01PM  Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium GlobeNewswire
08:07AM  Is Lexicon Pharmaceuticals (NASDAQ:LXRX) Using Too Much Debt? Simply Wall St.
Jan-09-20 02:50PM  Top Biotech Stocks for Q1 2020 Investopedia
Jan-06-20 06:09PM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
Dec-20-19 08:31AM  Lexicon shares fall on diabetes study data MarketWatch
07:00AM  Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes GlobeNewswire
Dec-19-19 08:28PM  Were Hedge Funds Right About Betting On Lexicon Pharmaceuticals, Inc. (LXRX)? Insider Monkey
Dec-13-19 08:52AM  Implied Volatility Surging for Lexicon (LXRX) Stock Options Zacks
Dec-05-19 12:54PM  How Much is Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) CEO Getting Paid? Simply Wall St. +12.20%
07:00AM  Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 GlobeNewswire
Dec-03-19 07:00AM  Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer GlobeNewswire
Dec-02-19 11:09AM  Why Lexicon Pharma Shares Are Moving Lower Benzinga -10.48%
09:57AM  FDA denies appeal of decision over Lexicon Pharmas diabetes drug Yahoo Finance Video
07:58AM  UPDATE: Lexicon Pharmaceuticals stock slides 31% after FDA denies appeal of decision relating to diabetes drug MarketWatch
07:00AM  Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDAs Office of New Drugs for Sotagliflozin in Type 1 Diabetes GlobeNewswire
Nov-26-19 04:01PM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire -6.02%
Nov-15-19 11:17PM  Edited Transcript of LXRX earnings conference call or presentation 7-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-14-19 08:09PM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
09:10AM  Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now? Zacks
Nov-13-19 08:39AM  Top Ranked Value Stocks to Buy for November 13th Zacks
Nov-07-19 11:15AM  Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates Zacks
07:00AM  Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Oct-31-19 04:01PM  Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 GlobeNewswire
10:34AM  Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings Growth Zacks
Oct-30-19 10:34AM  Is Lexicon Pharmaceuticals, Inc. (LXRX) Going to Burn These Hedge Funds? Insider Monkey
Oct-29-19 07:05AM  NASDAQ: LXRX Investor Notice: Update in Lawsuit against Lexicon Pharmaceuticals, Inc. announced by Shareholders Foundation ACCESSWIRE
Oct-15-19 11:29AM  Introducing Lexicon Pharmaceuticals (NASDAQ:LXRX), The Stock That Tanked 80% Simply Wall St.
Oct-13-19 05:15PM  New Sanofi CEO Looks to Shake Things Up GuruFocus.com
Oct-02-19 04:01PM  Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium GlobeNewswire
Sep-30-19 10:05AM  Small Caps Win in September: 5 Best ETFs & Stocks Zacks -12.37%
Sep-23-19 08:54AM  Are Options Traders Betting on a Big Move in Lexicon Pharmaceuticals (LXRX) Stock? Zacks -5.62%
Sep-18-19 08:42AM  Lexicon (LXRX) Catches Eye: Stock Jumps 7.3% Zacks +29.25%
Sep-15-19 11:18AM  The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck Benzinga
Sep-11-19 07:42PM  Woodlands-based pharma co. to receive $260M in drug dispute settlement American City Business Journals +27.91%
09:46AM  Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally Zacks
07:09AM  The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway Benzinga
Sep-10-19 04:51PM  Sanofi to pay Lexicon $260 mln for terminated partnership Reuters +21.13%
04:01PM  Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting GlobeNewswire
04:01PM  Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi GlobeNewswire
Sep-09-19 03:38PM  Market Sentiment Around Loss-Making Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Simply Wall St.
Sep-05-19 11:12AM  Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class? Motley Fool
Aug-30-19 07:00AM  Lexicon Pharmaceuticals To Present At Upcoming Investor Conference GlobeNewswire
Aug-27-19 01:59AM  Edited Transcript of LXRX earnings conference call or presentation 31-Jul-19 12:00pm GMT Thomson Reuters StreetEvents
Aug-20-19 07:15PM  Lexicon Pharmaceuticals Inc (LXRX) President and CEO Lonnel Coats Bought $54,000 of Shares GuruFocus.com -6.38%
Aug-09-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire +19.53%
Aug-08-19 05:23PM  Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes GlobeNewswire
Jul-31-19 11:36AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates Zacks -18.67%
09:15AM  Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:00AM  Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Jul-30-19 12:59PM  Lexicon Pharmaceuticals Announces Date Change for Second Quarter 2019 Financial Results Conference Call and Webcast to July 31, 2019 GlobeNewswire
Jul-29-19 04:35PM  Why Cooper Tire & Rubber, Insperity, and Lexicon Pharmaceuticals Slumped Today Motley Fool -70.30%
12:14PM  Here's Why Lexicon Pharmaceuticals Is Collapsing Today Motley Fool
08:53AM  Lexicon's stock loses more than half its value after Sanofi's notice to end alliance MarketWatch
Jul-27-19 05:05AM  Sanofi ends partnership with Lexicon to develop add-on pill for diabetes Reuters
Jul-26-19 05:58PM  UPDATE 1-Sanofi ends partnership with Lexicon to develop add-on pill for diabetes Reuters
05:15PM  Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista (Sotagliflozin) Type 2 Diabetes Phase 3 Program GlobeNewswire
05:05PM  Sanofi ends partnership with Lexicon to develop diabetes drug Reuters
10:15AM  How Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Can Impact Your Portfolio Volatility Simply Wall St.
Jul-25-19 07:00AM  Lexicon Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on August 1, 2019 GlobeNewswire
Jul-22-19 10:31AM  Lexicon Pharmaceuticals (LXRX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-15-19 05:43PM  AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes Zacks
Jun-26-19 02:07PM  Here is What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX) Insider Monkey
Jun-13-19 07:21AM  Should You Be Pleased About The CEO Pay At Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Simply Wall St.
Jun-04-19 07:00AM  Lexicon Pharmaceuticals to Present New Clinical Data at 79th American Diabetes Association Scientific Sessions GlobeNewswire
May-23-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
May-08-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire
May-07-19 01:38PM  Edited Transcript of LXRX earnings conference call or presentation 1-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-05-19 08:13PM  Heres What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. (LXRX) Insider Monkey
May-01-19 01:16PM  Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates Zacks
11:49AM  Lexicon Pharmaceuticals Inc (LXRX) Q1 2019 Earnings Call Transcript Motley Fool
07:30AM  Lexicon: 1Q Earnings Snapshot Associated Press
07:00AM  Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update GlobeNewswire
Apr-26-19 04:02PM  ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes GlobeNewswire +5.11%
04:01PM  Zynquista now Approved in the European Union for Treatment of Adults With Type 1 Diabetes GlobeNewswire
Apr-25-19 10:34AM  Will Lexicon Pharmaceuticals (LXRX) Report Negative Q1 Earnings? What You Should Know Zacks
07:00AM  Lexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019 GlobeNewswire
Apr-03-19 07:07AM  Did You Manage To Avoid Lexicon Pharmaceuticals's (NASDAQ:LXRX) Painful 55% Share Price Drop? Simply Wall St.
Apr-02-19 07:00AM  Lexicon Pharmaceuticals to Present at Upcoming Investor Conference GlobeNewswire +5.14%
Apr-01-19 02:20PM  CLASS ACTION UPDATE for LXRX, BRS, WTW and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the treatment of type 1 and is in Phase III clinical trials for the treatment of type 2 diabetes; LX9211, which is in Phase I clinical development for the treatment of neuropathic pain; and LX2761 that is in Phase I clinical development for the treatment of diabetes. The company has strategic collaboration and license agreements with Ipsen Pharma SAS; Bristol-Myers Squibb Company; and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SOBECKI CHRISTOPHER JDirectorApr 26Option Exercise0.003,4660140,759Apr 27 04:48 PM
Swain Judith LDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:49 PM
Palantoni FrankDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:48 PM
NIES ALAN SDirectorApr 26Option Exercise0.003,466017,082Apr 27 04:47 PM
DEBBANE RAYMONDDirectorApr 26Option Exercise0.003,4660316,883Apr 27 04:45 PM
LEFKOWITZ ROBERT J MDDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:46 PM
BARKER SAM LDirectorApr 26Option Exercise0.003,466055,653Apr 27 04:44 PM
Amouyal PhilippeDirectorApr 26Option Exercise0.003,466016,368Apr 27 04:43 PM
COATS LONNELPresident and CEOSep 18Buy3.1050,000155,000227,539Sep 19 04:28 PM
Santini Alexander AEVP and CCOSep 18Buy3.364,50015,11518,661Sep 19 04:26 PM
COATS LONNELPresident and CEOSep 17Buy3.1350,000156,403177,539Sep 18 04:39 PM
DEBBANE RAYMONDDirectorSep 16Buy2.7293,773254,785313,417Sep 17 05:36 PM
SOBECKI CHRISTOPHER JDirectorSep 16Buy2.5525,00063,718137,293Sep 17 05:27 PM
DEBBANE RAYMONDDirectorSep 13Buy2.469,26922,806219,644Sep 17 05:36 PM
DEBBANE RAYMONDDirectorSep 13Buy2.40197,473474,760210,375Sep 17 05:33 PM
SOBECKI CHRISTOPHER JDirectorSep 13Buy2.4199,249238,750112,293Sep 17 05:23 PM
COATS LONNELPresident and CEOAug 19Buy1.403,0004,194127,539Aug 20 05:02 PM
COATS LONNELPresident and CEOAug 16Buy1.3537,00049,835124,539Aug 20 05:02 PM
Tessmer James FVP, Finance & AccountingAug 02Buy1.1410,00011,40043,368Aug 02 04:15 PM
BARKER SAM LDirectorAug 02Buy1.1824,00028,20052,187Aug 02 04:12 PM